Stock Events

Stock Events

Addex Therapeutics 

€2.62
15
+€0.08+3.15%Wednesday 06:04

Statistics

Day High
2.62
Day Low
2.62
52W High
8
52W Low
2.54
Volume
0
Avg. Volume
0
Mkt Cap
4.59M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 9Expected
Q3 2025
Q1 2026
Next
-0.01
-0.01
-0
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-22,346.57%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
32,094.96Revenue
-7.17MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow APE1.MU. It's not an investment recommendation.
Apple
2
AAPL
Amazon
2
AMZN
NVIDIA
2
NVDA
AMD
2
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap7.61B
Alkermes plc operates in the CNS therapeutic area, making it a direct competitor to Addex Therapeutics in developing treatments for neurological disorders.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.55B
ACADIA Pharmaceuticals specializes in CNS disorders, including Parkinson’s disease psychosis, directly competing with Addex's focus areas.
BridgeBio Pharma
BBIO
Mkt Cap14.6B
BridgeBio Pharma targets genetic diseases and cancers, including neurological disorders, overlapping with Addex Therapeutics' research focus.
Biogen
BIIB
Mkt Cap37.49B
Biogen is a major player in neurodegenerative diseases, Alzheimer's, and multiple sclerosis, competing in the CNS space.
AMGEN
AMGN
Mkt Cap251.94B
Amgen's broad focus on innovative therapeutics includes CNS disorders, positioning it as a competitor in the neurological space.
Palatin Technologies
PTN
Mkt Cap8.9M
Palatin Technologies works on developing therapeutics for diseases with a focus on CNS, making it a competitor in the neurological treatment market.
Novartis
NVS
Mkt Cap303.67B
Novartis has a diversified portfolio that includes treatments for neurological conditions, competing with Addex in the broader CNS therapeutic area.
Pfizer
PFE
Mkt Cap173.95B
Pfizer has a wide range of therapeutic areas, including CNS disorders, making it a competitor in developing treatments for neurological conditions.

About

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
Show More
CEO
Timothy Mark Dyer
Employees
3
Country
Switzerland
ISIN
US00654J2069
WKN
000A3EXC6

Listings

MU
DE
APE.MU
STU
DE
APE1.STU
MU
DE
APE0.MU
LSE
GB
0QNV.LSE

0 Comments

Share your thoughts

FAQs

What is Addex Therapeutics stock price today?▼
The current price of APE1.MU is €2.62 EUR — it has increased by +3.15% in the past 24 hours. Watch Addex Therapeutics stock price performance more closely on the chart.
What is Addex Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Addex Therapeutics stocks are traded under the ticker APE1.MU.
Is Addex Therapeutics stock price growing?▼
APE1.MU stock has risen by +0% compared to the previous week, the month change is a -4.38% fall, over the last year Addex Therapeutics has showed a -67.25% decrease.
What is Addex Therapeutics market cap?▼
Today Addex Therapeutics has the market capitalization of 4.59M
When is the next Addex Therapeutics earnings date?▼
Addex Therapeutics is going to release the next earnings report on November 9, 2026.
What were Addex Therapeutics earnings last quarter?▼
APE1.MU earnings for the last quarter are -0.01 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Addex Therapeutics revenue for the last year?▼
Addex Therapeutics revenue for the last year amounts to 32,094.96 EUR.
What is Addex Therapeutics net income for the last year?▼
APE1.MU net income for the last year is -7.17M EUR.
How many employees does Addex Therapeutics have?▼
As of November 7, 2026, the company has 3 employees.
In which sector is Addex Therapeutics located?▼
Addex Therapeutics operates in the Health & Wellness sector.
When did Addex Therapeutics complete a stock split?▼
The last stock split for Addex Therapeutics was on October 23, 2023 with a ratio of 1:20.
Where is Addex Therapeutics headquartered?▼
Addex Therapeutics is headquartered in Geneva, Switzerland.